Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q3 2020 Earnings Presentation
18 slides from Bactiguard Holding Ab's earnings presentation, Nov 5, 2020
Slide 1: Bactiguard Q3 2020
Bactiguard Q3 2020 Investor presentation – November 5th 2020 Cecilia Edström, CEO Gabriella Björknert Caracciolo, CFO 1
Slide 2: External factors
External factors & Belgium cancels non-urgent surgery as full Covid lockdown looms Country moves closer to national shutdown as PM vows to protect health system Coronavirus - latest updates See all our coronavirus coverage INDIA NEWS A Medicg restrict News/India / Over 580,000 surgeries in India may
Slide 3: Financial summary
Financial summary Weak quarter but the need for infection prevention is greater than ever • Sales declined by 49% (-46% currency adjusted) to MSEK 34.1 (67.2) • BD license revenues of MSEK 20.2 (25.0) – 19% lower than last year • No new license revenue in the quarter – MSEK 29.4 from Zimmer Biomet i
Slide 4: Licensing partnerships
Licensing partnerships License partner Application area Territory Status Urinary catheter(Foley) The USA, Japan, the Recurring sales and UK, Ireland, Canada revenues and Australia Orthopedic trauma Global agreement excl. Milestone driven implants South-East Asia regulatory phase EU, US Well Lea
Slide 5: Recent trends
Recent trends • 60-80% fewer elective surgeries in the US • 50% fewer planned interventions in Stockholm, • and 25% fewer cancer diagnoses 5
Slide 6: BIP sales
BIP sales Recent digital initiatives and opportunities 6
Slide 7: Hydrocyn Aqua
Hydrocyn Aqua Advanced disinfection and wound care portfolio Future line extensions • Nasal spray • Dental wash • Baby care • Animal care • Eye spray 7
Slide 8: Strengthening the management and sales team
Strengthening the management and sales team • New General Manager Nordics Healthcare and homecare providers, pharmacies, B2B, B2C • New General Manager South East Asia Leading Malaysian sales team and distributor sales in the region • New Chief Marketing and Communications Officer Brand and digital
Slide 9: Financial update
& Bactiguard Financial update
Slide 10: Our business model
Our business model Expanding our portfolio for infection protection License agreements for various Proprietary product portfolio – applications with Bactiguard sold through distributors technology 10
Slide 11: Negative Covid-19 impact on earnings
Negative Covid-19 impact on earnings Q3 2020 vs 2019 • Revenue Growth of -49%, (adjusted for currency -46%) • Negative Covid-19 effect on license revenues from BD • No new license revenue (last year MSEK 29.4) • EBITDA-margin decreased to -9% (54%) • Low sales of BIP products, but acquisition of Vig
Slide 12: Financial overview
Financial overview 2020 2019 Full MSEK Q1 Q2 Q3 YTD 9m RTM Q1 Q2 Q3 YTD 9m Q4 year Revenues 48,1 48,2 34,1 130,5 190,3 33,9 33,0 67,2 134,1 59,8 193,9 EBITDA 14,4 10,5 -3,1 21,8 34,0 7,2 5,7 36,5 49,4 12,2 61,6 EBITDA margin % 30% 22% -9% 17% 18% 21% 17% 54% 37% 20% 32% Depreciations -10,5 -11,3 -11
Slide 13: Cash flow and liquidity
Cash flow and liquidity • The Vigilenz acquisition was partly financed by debt issue of new shares in Q2 2020 • Negative operating cash flow for Q3 of MSEK -3.3 (23.9) • Credit facility of 30 MSEK of which MSEK 13,9 utilised • Available liquidity incl credit facility amounted to MSEK 35.5 compared t
Slide 14: Clear growth strategy
Clear growth strategy Effective and safe Recurring license Broader product technology for revenues and new portfolio and infection agreements market coverage prevention
Slide 15: Updated long term financial targets
Updated long term financial targets Growth • Average revenue growth of 20% per year over a five year period 2025 (unchanged) Profitability • EDITDA margin of at least 30% at the end of the five-year period (unchanged) Dividend • A long-term goal to achieve a dividend of 30-50% of profit after tax, t
Slide 16: Infection prevention more needed than ever
Infection prevention more needed than ever 16
Slide 17: Questions & Answers
Questions & Answers Cecilia Edström CEO Phone +46 8 440 58 80 cecilia.edstrom@bactiguard.se Gabriella Björknert Caracciolo CFO Phone +46 8 440 58 80 Gabriella.caracciolo@bactiguard.se 17
Slide 18: Upcoming financial reports
Upcoming financial reports February 04, 2021 Year-end report for 2020 18